2nd Quarter - Report

REGENERON PHARMACEUTICALS, INC for REGENERON PHARMACEUTICALS, INC

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space.

LobbyistCovered position, as disclosed
MADDIE DAVIDSON —
EBEN DUROSS —
KATHERINE HADDAD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.

LobbyistCovered position, as disclosed
MADDIE DAVIDSON —
KATHERINE HADDAD —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual property legislation related to biopharmaceutical manufacturers.

LobbyistCovered position, as disclosed
MADDIE DAVIDSON —
EBEN DUROSS —
KATHERINE HADDAD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Trade and tariff issues related to corporations.

LobbyistCovered position, as disclosed
MADDIE DAVIDSON —
EBEN DUROSS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax and inflation issues related to corporations.

LobbyistCovered position, as disclosed
MADDIE DAVIDSON —
EBEN DUROSS —
KATHERINE HADDAD —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.